Literature DB >> 12437048

Clinics in diagnostic imaging (75). HIV encephalopathy and cerebral aneurysmal arteriopathy.

P Visrutaratna1, K Oranratanachai.   

Abstract

A six-year-old girl with vertically-transmitted HIV infection had hyperreflexia. MR imaging showed diffuse prominence of the subarachnoid spaces and ventricles caused by HIV encephalopathy. Fusiform dilatation of the supraclinoid segment of the right internal carotid artery was also noted. MR angiography confirmed cerebral aneurysmal arteriopathy. Imaging findings of the various cerebral manifestations and complications found in children with AIDS coming from the primary effects of HIV, opportunistic infections, tumours, and vascular disease are discussed.

Entities:  

Mesh:

Year:  2002        PMID: 12437048

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  4 in total

Review 1.  HIV and cerebral aneurysms.

Authors:  Ketan R Bulsara; Ali Raja; Justin Owen
Journal:  Neurosurg Rev       Date:  2004-12-24       Impact factor: 3.042

2.  Arterial dissection and subarachnoid haemorrhage in human immunodeficiency virus-infected patients. A report of three cases.

Authors:  A Taylor; D Lefeuvre; A Levy; S Candy
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

3.  Central Nervous System Vasculopathy in HIV-Infected Children Enrolled in the Pediatric AIDS Clinical Trials Group 219/219C Study.

Authors:  John S Schieffelin; Paige L Williams; Divna Djokic; Jeffrey P Anderson; Sharon Nachman; James M Oleske; George R Seage; Russell B Van Dyke
Journal:  J Pediatric Infect Dis Soc       Date:  2012-10-26       Impact factor: 3.164

4.  Neurologic abnormalities in HIV-1 infected children in the era of combination antiretroviral therapy.

Authors:  Lotus A van Arnhem; Madeleine J Bunders; Henriette J Scherpbier; Charles B L M Majoie; Liesbeth Reneman; Olivier Frinking; Bwee Tien Poll-The; Taco W Kuijpers; Dasja Pajkrt
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.